LT3495380T - Ko-agonistai gliukagonas ir glp-1, skirti nutukimo gydymui - Google Patents

Ko-agonistai gliukagonas ir glp-1, skirti nutukimo gydymui

Info

Publication number: LT3495380T
Authority: LT; Lithuania
Prior art keywords: glp; glucagon; obesity; agonists; treatment
Prior art date: 2012-12-11

Application number

LTEP18182274.3T

Other languages

English (en)

Inventor

Balaji AGORAM

Madeleine ANTONSSON

Maria Bednarek

Nicole BURMEISTER

Lambertus BENTHEM

David FAIRMAN

Maria FRITSCH-FREDIN

Ronald Henry Jackson

Rasmus Jansson Lofmark

Jaqueline METCALFE

Original Assignee

Medimmune Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-11

Filing date

2013-12-10

Publication date

2022-06-27

2013-12-10 Application filed by Medimmune Limited filed Critical Medimmune Limited

2022-06-27 Publication of LT3495380T publication Critical patent/LT3495380T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

LTEP18182274.3T 2012-12-11 2013-12-10 Ko-agonistai gliukagonas ir glp-1, skirti nutukimo gydymui LT3495380T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261735823P	2012-12-11	2012-12-11

Publications (1)

Publication Number	Publication Date
LT3495380T true LT3495380T (lt)	2022-06-27

Family

ID=50588751

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP13849992.6T LT2931745T (lt)	2012-12-11	2013-12-10	Gliukagono/glp-1 agonistai nutukimo gydymui
LTEP18182274.3T LT3495380T (lt)	2012-12-11	2013-12-10	Ko-agonistai gliukagonas ir glp-1, skirti nutukimo gydymui

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP13849992.6T LT2931745T (lt)	2012-12-11	2013-12-10	Gliukagono/glp-1 agonistai nutukimo gydymui

Country Status (26)

Country	Link
US (4)	US9765130B2 (lt)
EP (2)	EP2931745B1 (lt)
JP (1)	JP6490011B2 (lt)
KR (1)	KR102080366B1 (lt)
CN (2)	CN109776670A (lt)
AR (1)	AR093903A1 (lt)
AU (3)	AU2013356934C1 (lt)
BR (1)	BR112015012238B1 (lt)
CA (1)	CA2893445C (lt)
CY (2)	CY1121114T1 (lt)
DK (2)	DK3495380T3 (lt)
ES (2)	ES2698329T3 (lt)
HR (2)	HRP20181678T1 (lt)
HU (1)	HUE039952T2 (lt)
LT (2)	LT2931745T (lt)
MX (2)	MX388904B (lt)
PL (2)	PL3495380T3 (lt)
PT (2)	PT2931745T (lt)
RS (2)	RS63305B1 (lt)
RU (2)	RU2018137842A (lt)
SG (2)	SG10201801159WA (lt)
SI (2)	SI2931745T1 (lt)
SM (2)	SMT201800611T1 (lt)
TR (1)	TR201815172T4 (lt)
TW (2)	TWI617574B (lt)
WO (1)	WO2014091316A2 (lt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) *	2012-12-11	2018-03-11	梅迪繆思有限公司	用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
SG11201503526UA (en)	2012-12-21	2015-06-29	Sanofi Sa	Dual glp1/gip or trigonal glp1/gip/glucagon agonists
US9714277B2 (en) *	2013-03-14	2017-07-25	Medimmune Limited	Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
EP3080150B1 (en)	2013-12-13	2018-08-01	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
WO2015086729A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/gip receptor agonists
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
CN104926934B (zh) *	2014-09-23	2016-11-09	蒋先兴	胃泌酸调节素类似物
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en)	2015-06-12	2016-12-15	Sanofi	Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI622596B (zh) *	2015-10-26	2018-05-01	美國禮來大藥廠	升糖素受體促效劑
CN113546159B (zh)	2015-12-29	2023-09-08	派格生物医药(苏州)股份有限公司	包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
SG10202109721PA (en) *	2016-03-10	2021-10-28	Medimmune Ltd	Glucagon and glp-1 co-agonists for the treatment of obesity
EP3463423A4 (en) *	2016-06-02	2019-05-08	Indiana University Research & Technology Corporation	GLUCAGON-T3 CONJUGATES
CN107281471A (zh) *	2017-06-26	2017-10-24	中国药科大学	一种改构的胰高血糖素样肽－1及其修饰物的应用
EP3708577B1 (en) *	2017-11-06	2024-09-04	Shenzhen Turier Biotech Co., Ltd.	Treatment of biliary cirrhosis based on oxyntomodulin analogue glp-1r/gcgr dual-target agonist peptide
TWI770085B (zh) *	2017-11-21	2022-07-11	日商武田藥品工業股份有限公司	胜肽化合物
ES2925678T3 (es)	2018-04-05	2022-10-19	Sun Pharmaceutical Ind Ltd	Nuevos análogos de GLP-1
CN111171134B (zh)	2018-11-12	2023-08-15	天津药物研究院有限公司	胰高血糖素衍生肽及其用途
SG11202112478PA (en)	2019-05-21	2021-12-30	Medimmune Ltd	Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
KR20220027204A (ko)	2019-07-01	2022-03-07	메디뮨 리미티드	글루카곤 및 glp-1 공동작용제 펩타이드의 제약 조성물
CN112898406B (zh) *	2019-10-12	2023-11-10	深圳纳福生物医药有限公司	不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
EP4069720A4 (en) *	2019-12-03	2023-12-27	MedImmune, LLC	COMBINATION THERAPY WITH GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY
TW202140061A (zh)	2020-01-10	2021-11-01	英商梅迪繆思有限公司	用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑
CN113493503B (zh) *	2020-04-08	2022-08-05	浙江道尔生物科技有限公司	一种肠促胰岛素类似物及其制备方法和用途
CN115484972B (zh)	2020-04-24	2025-07-01	勃林格殷格翰国际有限公司	作为长效glp-1/升糖素受体激动剂以治疗脂肪肝疾病及脂肪肝炎的升糖素类似物
TW202313974A (zh)	2021-06-08	2023-04-01	瑞典商阿斯特捷利康公司	用於治療肝病之組合療法
JP2024529452A (ja)	2021-07-30	2024-08-06	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	長時間作用型ｇｌｐ１／グルカゴン受容体アゴニストのための投薬レジメン
TW202346323A (zh)	2022-02-07	2023-12-01	英商梅迪繆思有限公司	具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽
CN121398810A (zh) *	2022-11-03	2026-01-23	Efil生物科学有限公司	包含glp-1受体激动剂和acat抑制剂的组合物
WO2024123812A1 (en)	2022-12-05	2024-06-13	Shattuck Labs, Inc.	Fusion proteins for the treatment of cardiometabolic diseases
WO2024165571A2 (en)	2023-02-06	2024-08-15	E-Therapeutics Plc	Inhibitors of expression and/or function
CN115975057B (zh) *	2023-03-16	2023-05-16	杭州信海医药科技有限公司	一种可妥度肽的固相合成方法
CN121285571A (zh)	2023-06-09	2026-01-06	太阳医药工业有限公司	Glp-1/gip双重、glp-1/gcg双重和glp-1/gip/gcg三重受体激动剂
WO2025024788A1 (en) *	2023-07-27	2025-01-30	Biomedit, Llc	Stabilized glp-1 peptides and dual agonist peptides against glp-1r and gipr and methods of use thereof
WO2025125576A2 (en)	2023-12-15	2025-06-19	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025133348A1 (en)	2023-12-22	2025-06-26	E-Therapeutics Plc	Inhibitors of expression and/or function
EP4686757A1 (en)	2024-07-31	2026-02-04	e-therapeutics PLC	Inhibitors of expression and/or function
WO2025196502A1 (en)	2024-03-20	2025-09-25	North Carolina Agricultural & Technical State University	Choline kinase inhibitors as a therapeutic treatment for obesity
WO2025242620A1 (en)	2024-05-20	2025-11-27	Medimmune Limited	Polypeptide combinations and uses thereof
CN118787658B (zh) *	2024-06-14	2025-01-21	中国农业大学	一种胰高血糖素样肽-1受体特异性核酸适配体在代谢疾病干预中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US30326A (en) *		1860-10-09		Steam-g-eneratob
DE3572982D1 (en)	1984-03-06	1989-10-19	Takeda Chemical Industries Ltd	Chemically modified lymphokine and production thereof
CA2006596C (en)	1988-12-22	2000-09-05	Rika Ishikawa	Chemically-modified g-csf
CA2497794A1 (en) *	2002-09-06	2004-03-18	Bayer Pharmaceuticals Corporation	Modified glp-1 receptor agonists and their pharmacological methods of use
CN1938334A (zh) *	2004-01-30	2007-03-28	瓦拉塔药品公司	Glp－1激动剂和胃泌素化合物的联合使用
DE102004043153B4 (de) *	2004-09-03	2013-11-21	Philipps-Universität Marburg	Erfindung betreffend GLP-1 und Exendin
EA014647B1 (ru) *	2005-08-11	2010-12-30	Амилин Фармасьютикалз, Инк.	Гибридные полипептиды с селектируемыми свойствами
CN1935846A (zh) *	2005-09-14	2007-03-28	王庆华	一种用于治疗糖尿病的融合蛋白及其制备方法和应用
NZ580670A (en)	2007-06-21	2011-09-30	Univ Muenchen Tech	Biological active proteins having increased in vivo and/or vitro stability
EP2214691B1 (en) *	2007-10-30	2015-09-30	Indiana University Research and Technology Corporation	Compounds exhibiting glucagon antagonist and glp-1 agonist activity
MX2011013625A (es)	2009-06-16	2012-01-20	Univ Indiana Res & Tech Corp	Compuestos glucagon activo de receptor de gip.
ES2661228T3 (es) *	2010-05-13	2018-03-28	Indiana University Research And Technology Corporation	Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
TWI617574B (zh) *	2012-12-11	2018-03-11	梅迪繆思有限公司	用於治療肥胖之升糖素與ｇｌｐ－１共促效劑

2013
- 2013-12-05 TW TW102144692A patent/TWI617574B/zh active
- 2013-12-05 TW TW107102837A patent/TWI674270B/zh active
- 2013-12-10 AU AU2013356934A patent/AU2013356934C1/en not_active Ceased
- 2013-12-10 CA CA2893445A patent/CA2893445C/en active Active
- 2013-12-10 MX MX2019006260A patent/MX388904B/es unknown
- 2013-12-10 PL PL18182274.3T patent/PL3495380T3/pl unknown
- 2013-12-10 DK DK18182274.3T patent/DK3495380T3/da active
- 2013-12-10 SI SI201331220T patent/SI2931745T1/sl unknown
- 2013-12-10 EP EP13849992.6A patent/EP2931745B1/en active Active
- 2013-12-10 PT PT13849992T patent/PT2931745T/pt unknown
- 2013-12-10 WO PCT/IB2013/003191 patent/WO2014091316A2/en not_active Ceased
- 2013-12-10 HU HUE13849992A patent/HUE039952T2/hu unknown
- 2013-12-10 PL PL13849992T patent/PL2931745T3/pl unknown
- 2013-12-10 TR TR2018/15172T patent/TR201815172T4/tr unknown
- 2013-12-10 EP EP18182274.3A patent/EP3495380B1/en active Active
- 2013-12-10 US US14/650,469 patent/US9765130B2/en active Active
- 2013-12-10 SM SM20180611T patent/SMT201800611T1/it unknown
- 2013-12-10 BR BR112015012238-8A patent/BR112015012238B1/pt active IP Right Grant
- 2013-12-10 RS RS20220574A patent/RS63305B1/sr unknown
- 2013-12-10 SI SI201331995T patent/SI3495380T1/sl unknown
- 2013-12-10 SM SM20220266T patent/SMT202200266T1/it unknown
- 2013-12-10 LT LTEP13849992.6T patent/LT2931745T/lt unknown
- 2013-12-10 JP JP2015546105A patent/JP6490011B2/ja active Active
- 2013-12-10 DK DK13849992.6T patent/DK2931745T3/en active
- 2013-12-10 LT LTEP18182274.3T patent/LT3495380T/lt unknown
- 2013-12-10 SG SG10201801159WA patent/SG10201801159WA/en unknown
- 2013-12-10 CN CN201910117184.2A patent/CN109776670A/zh active Pending
- 2013-12-10 HR HRP20181678TT patent/HRP20181678T1/hr unknown
- 2013-12-10 MX MX2015006568A patent/MX365458B/es active IP Right Grant
- 2013-12-10 HR HRP20220734TT patent/HRP20220734T1/hr unknown
- 2013-12-10 KR KR1020157015139A patent/KR102080366B1/ko active Active
- 2013-12-10 RS RS20181267A patent/RS57899B1/sr unknown
- 2013-12-10 ES ES13849992T patent/ES2698329T3/es active Active
- 2013-12-10 PT PT181822743T patent/PT3495380T/pt unknown
- 2013-12-10 ES ES18182274T patent/ES2926713T3/es active Active
- 2013-12-10 RU RU2018137842A patent/RU2018137842A/ru unknown
- 2013-12-10 RU RU2015127780A patent/RU2671088C2/ru active
- 2013-12-10 CN CN201380062842.3A patent/CN104822699B/zh active Active
- 2013-12-10 AR ARP130104612A patent/AR093903A1/es unknown
- 2013-12-10 SG SG11201503230XA patent/SG11201503230XA/en unknown
2017
- 2017-08-10 US US15/673,826 patent/US10556939B2/en active Active
- 2017-11-15 AU AU2017261505A patent/AU2017261505C1/en not_active Ceased
2018
- 2018-11-21 CY CY181101228T patent/CY1121114T1/el unknown
2019
- 2019-11-29 AU AU2019272054A patent/AU2019272054A1/en not_active Abandoned
- 2019-12-20 US US16/723,645 patent/US11230584B2/en active Active
2021
- 2021-12-14 US US17/550,269 patent/US20220098265A1/en not_active Abandoned
2022
- 2022-06-24 CY CY20221100439T patent/CY1125302T1/el unknown

Also Published As

Publication number	Publication date
CY1125302T1 (el)	2025-03-28
HUE039952T2 (hu)	2019-02-28
BR112015012238B1 (pt)	2022-03-29
KR20150093167A (ko)	2015-08-17
SI3495380T1 (sl)	2022-08-31
MX2019006260A (es)	2019-08-14
HRP20181678T1 (hr)	2019-03-08
SMT202200266T1 (it)	2022-07-21
AR093903A1 (es)	2015-06-24
AU2017261505C1 (en)	2020-07-30
WO2014091316A3 (en)	2014-10-30
ES2926713T3 (es)	2022-10-27
RU2018137842A (ru)	2018-12-13
HK1216179A1 (en)	2016-10-21
SG11201503230XA (en)	2015-06-29
US20200115431A1 (en)	2020-04-16
AU2017261505B2 (en)	2019-10-10
MX388904B (es)	2025-03-20
TWI617574B (zh)	2018-03-11
TW201427993A (zh)	2014-07-16
MX365458B (es)	2019-06-04
RU2018137842A3 (lt)	2022-04-01
EP3495380B1 (en)	2022-03-30
PT3495380T (pt)	2022-06-28
RU2015127780A (ru)	2017-01-19
SG10201801159WA (en)	2018-03-28
AU2019272054A1 (en)	2020-01-02
CN109776670A (zh)	2019-05-21
JP6490011B2 (ja)	2019-03-27
ES2698329T3 (es)	2019-02-04
US20170342121A1 (en)	2017-11-30
EP2931745A2 (en)	2015-10-21
CN104822699A (zh)	2015-08-05
KR102080366B1 (ko)	2020-02-21
BR112015012238A2 (lt)	2017-08-15
SMT201800611T1 (it)	2019-01-11
RS57899B1 (sr)	2019-01-31
PL2931745T3 (pl)	2019-04-30
AU2013356934B2 (en)	2017-08-17
US9765130B2 (en)	2017-09-19
CN104822699B (zh)	2019-03-01
CA2893445A1 (en)	2014-06-19
US10556939B2 (en)	2020-02-11
AU2013356934A1 (en)	2015-05-21
PT2931745T (pt)	2018-11-29
RS63305B1 (sr)	2022-07-29
RU2671088C2 (ru)	2018-10-29
DK2931745T3 (en)	2018-12-10
US20220098265A1 (en)	2022-03-31
TW201829452A (zh)	2018-08-16
DK3495380T3 (da)	2022-06-20
MX2015006568A (es)	2015-08-05
EP2931745B1 (en)	2018-08-22
WO2014091316A2 (en)	2014-06-19
CA2893445C (en)	2020-06-02
JP2016501256A (ja)	2016-01-18
US11230584B2 (en)	2022-01-25
AU2017261505A1 (en)	2017-12-07
PL3495380T3 (pl)	2022-08-01
US20150307579A1 (en)	2015-10-29
TWI674270B (zh)	2019-10-11
LT2931745T (lt)	2018-11-12
SI2931745T1 (sl)	2018-11-30
HRP20220734T1 (hr)	2022-09-02
EP3495380A1 (en)	2019-06-12
AU2013356934C1 (en)	2018-07-05
TR201815172T4 (tr)	2018-11-21
CY1121114T1 (el)	2019-12-11

Publication	Publication Date	Title
PL3495380T3 (pl)	2022-08-01	Współagoniści glukagonu i glp-1 do leczenia otyłości
ZA201309626B (en)	2017-09-27	Glucagon/glp-1 reeptor co-agonists
ZA201806637B (en)	2019-07-31	Glucagon and glp-1 co-agonists for the treatment of obesity
EP2739144A4 (en)	2015-04-01	COMPOUNDS AND ITS THERAPEUTIC USE
PL3021838T3 (pl)	2021-03-08	Leczenie otyłości
ZA201502290B (en)	2016-01-27	2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and ist associated disorders
EP2867239A4 (en)	2015-12-23	OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
SI2900230T1 (sl)	2019-01-31	Sestavki za zdravljenje debelosti in postopki njihove uporabe
ZA201501503B (en)	2016-01-27	Bio-inoculant and use thereof for treatment of effluents
IL238126A0 (en)	2015-05-31	Compositions for the treatment and prevention of obesity
SI3074033T1 (sl)	2019-03-29	Spojine za zdravljenje debelosti in postopki njihove uporabe
ZA201408065B (en)	2016-04-28	Compositions and methods for the treatment of diabetes
IL235066A0 (en)	2014-12-31	Sorcs1 for use in the treatment of obesity and overweight
ZA201404738B (en)	2016-10-26	Treatment of type i and type ii diabetes